PCI Pharma Services has invested USD $365m into infrastructure at its European and North American sites.
The biopharma CDMO has expanded its facilities to support the clinical and commercial-scale final assembly and packaging of drug-device combination products with advanced delivery systems.
This extension in the company's capabilities comes off the back of recent new business, and is a strategic investment that allows the company to accomodate further growth and demand.
Recently, PCI has also placed heavy investments into its automated drug delivery technologies to enhance the capabilities of the company's Biotech Centre of Excellence in Philadelphia.
Together with the extension of PCI's packaging capabilities, the company can now manage the full lifespan of such products — from sterile drug product development and manufacturing through to clinical trial supply, product launch and commercialisation.
The US site
In the US, PCI has further plans to expand its Rockford, Illinois site by 545,000 sqft, which will be dedicated to advanced drug delivery and drug-device combination assembly and packaging.
The site will now include 345,000 sqft for advanced drug delivery injectable packaging, with an additional 130,000 sqft of warehousing space to store products in every development phase.
It will have the capability to process, assemble and package vials, autoinjectors, prefilled syringes and pen-cartridge combinations.
PCI is also planning to further expand the site by 70,000 sqft, which will focus on advanced drug delivery and patient-centric drug-device combination assembly and packaging.
This plant will likely be brought into full operation in two phases, with construction estimated to begin in the latter half of 2025.
The European site
The company is also bolstering its presence in Europe with a newly acquired pharmaceutical packaging and device assembly facility near Dublin, Ireland.
The site will provide temperature-controlled storage capabilities, as well as commercial-scale packaging and assembly operations for both injectables and OSD drug products.
PCI is also building a packaging and device assembly service facility at its existing Dublin campus, which will allow for the final assembly, labelling and packaging of injectables.
The facility will also house cold chain packaging and temperature-controlled storage.
CEO of PCI Pharma Services, Salim Haffar, commented: “This substantial, multi-continent investment places PCI Pharma Services at the forefront of the global advanced drug delivery solutions and drug-device combination product assembly landscape,”
“The new and expanded facilities and infrastructure showcase our commitment to meeting evolving market and customer needs for clinical-to-commercial drug-device final assembly and packaging, and furthers PCI’s overarching purpose of enabling life-changing therapies and patient convenience.”
